New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.